glp 1 drugs semaglutide Diabetes advocacy group discourages use of compounded GLP-1 Hair loss with GLP-1 drugs

pre- and post-operative treatment, when requirements are increased as in fever, severe burns, increased metabolism, pregnancy, gastrointestinal disorders interfering with intake or absorption of vitamins, prolonged or wasting diseases, alcoholism and where other deficiencies exist

Patients taking insulin or sulfonylureas alongside Wegovy may experience hypoglycaemia, which can present as fatigue, weakness, or confusion

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for managing type 2 diabetes (under the brand name Ozempic) and chronic weight management (Wegovy)

A decline in estrogen levels during menopause can lead to disruptions in sleep, particularly in the form of insomnia and fragmented sleep, which are common symptoms of the menopausal transition

For accurate identification, specific modifications were considered during the search